Bisphosphonates affect migration ability & cell viability of HUVEC, fibroblasts and osteoblasts in-vitro

Christian Walter (1) , Andreas Pabst (2) , Thomas Ziebart (2) , Marcus Oliver Klein (2) , B Al-Nawas (3)

1 Oral- and Maxillofacial Surgery
2 Oral- and Maxillofacial Surgery
3 Oral and Maxillofacial Surgery

Objective: Bisphosphonate-associated-osteonecrosis of the jaw (BP-ONJ) is a side effect in patients being treated with bisphosphonates. The bisphosphonates most often associated with BP-ONJ are the highly potent nitrogen-containing bisphosphonates e.g. pamidronate or zoledronate. In terms of BP-ONJ aetiology, several theories are being discussed: inhibition of bone remodelling, effect on soft tissues, and antiangiogenic effect of bisphosphonates. The aim of this in-vitro study was to investigate the effect of different potent bisphosphonates on osteoblasts, fibroblasts and human umbilicord vein endothelial cells (HUVEC). Materials and Methods: Three nitrogen-containing bisphosphonates (ibandronate, pamidronate and zoledronate) and one non-nitrogen-containing bisphosphonate (clodronate) were compared concerning their potency on apoptosis induction (tunnel), cell viability (calcein assay) and migration potency (boyden chamber) on osteoblasts, fibroblasts and HUVEC. Results: The nitrogen-containing bisphphosphonates, particularly pamidronate and zoledronate, affect cell viability, cell migration and the induction of apoptosis of osteoblasts, fibroblasts and HUVEC. Conclusions: These results support the theory that BP-ONJ is a multifactorially caused disease because several cell lines of the oral cavity which are responsible for integrity and wound healing are negatively affected by nitrogen-containing bisphosphonates. Perioperative interruption of bisphosphonate application during dental surgical procedures - if possible - might be feasible to promote better wound healing.

Mots clés: Medicine

Christian Walter, Andreas Pabst, Thomas Ziebart, Marcus Oliver Klein, B Al-Nawas. Bisphosphonates affect migration ability & cell viability of HUVEC, fibroblasts and osteoblasts in-vitro. Oral Diseases, 2010, 17 (2), pp.194. ⟨10.1111/j.1601-0825.2010.01720.x⟩. ⟨hal-00599899⟩